home / stock / hoth / hoth news


HOTH News and Press, Hoth Therapeutics Inc. From 07/09/20

Stock Information

Company Name: Hoth Therapeutics Inc.
Stock Symbol: HOTH
Market: NASDAQ
Website: hoththerapeutics.com

Menu

HOTH HOTH Quote HOTH Short HOTH News HOTH Articles HOTH Message Board
Get HOTH Alerts

News, Short Squeeze, Breakout and More Instantly...

HOTH - Voltron Therapeutics Retains Buenaventura Advisors, LLC to Explore Strategic Alternatives for its HaloVax(TM) Subsidiary

NEW YORK , July 09, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. (the Company) announced today it has retained Buenaventura Advisors, LLC to explore strategic alternatives for HaloVax, a biopharmaceutical company and special purpose subsidiary of Voltron Therapeutics, Inc.  ...

HOTH - Voltron Therapeutics, Inc. Initiates Animal Testing of Self-Assembling Vaccine in Fight Against COVID-19

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targe...

HOTH - Hoth Therapeutics partners with Virginia Commonwealth University for peptide COVID-19 treatment

Hoth Therapeutics ( HOTH +2.8% )  announces  sponsored research agreement with Virginia Commonwealth University for development of a potential COVID-19 treatment. More news on: Hoth Therapeutics, Inc., Healthcare stocks news, Read more ...

HOTH - Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment

NEW YORK , June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment. Research wil...

HOTH - Hoth Therapeutics Enters into Expanded Sponsored Research Agreement with the George Washington University for Dermatology Treatment Candidate WEG232

NEW YORK , June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for...

HOTH - Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White Paper

NEW YORK , June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters , Ph.D., Professor, Department of Chemi...

HOTH - Hoth Therapeutics receives notice of Allowance for US patent

Hoth Therapeutics ( HOTH +4.8% ) announces that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAMBA Retinamides that Degrade MNKs for Treating Cancer". More news on: Hoth Therapeu...

HOTH - Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology Conditions

NEW YORK , June 8, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Number: 15/528,317 related to "13-Cis-RAM...

HOTH - Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected

June 3, 2020 Palm Beach, FL – June 3, 2020 – Rapid development of a vaccine to prevent the global health crisis is a global imperative, and defining the stakes and potential hurdles is critical because regulatory and medical decisions are based on benefit/risk calcul...

HOTH - Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline

NEW YORK , June 3, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today provided an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as ...

Previous 10 Next 10